Dr. David Margulies
Q-State Co-Founder & Chairman of the Board
David Margulies currently serves as Chairman of Q-State Biosciences. As a physician executive and entrepreneur with interests in computational biology, genetics, and neuroscience, David has founded and led multiple technology-based health services companies. In the 1980s, he created the first clinical computing programs at both Columbia Presbyterian Medical Center and Boston Children’s Hospital, serving as Boston Children’s Hospital’s first Chief Information Officer. He then served as Executive Vice President, Chief Scientist, and Director of Cerner Corporation. David also co-founded and served in leadership roles at CareInsite (now WebMD), Correlagen Diagnostics (acquired by LabCorp), Generation Health (acquired by CVS/Caremark), and Claritas Genomics (now QnA Diagnostics). More recently, David returned to Boston Children’s Hospital as Vice President of Strategy and co-founded and served as Chief Executive Officer at Q-State Biosciences. David is a graduate of Amherst College and Harvard Medical School, and board certified in Internal Medicine. He holds an appointment as Assistant Professor at Harvard Medical School in the Department of Bioinformatics and at Boston Children’s Hospital in the Division of Genetics.
Founder & Chairman of Multiple Innovative Health Companies
Mark Evenstad is Founder and Chairman of MOBE, Pairnomix, Plymouth Guarantee, Healthware Technologies, ACOVA and Applied Insights. He served as CEO and Vice Chair of Upsher-Smith Laboratories through its sale to Sawai Pharmaceuticals in 2017. Mark is committed to discovering or inventing critical therapeutics and interventions that meaningfully and measurably impact the health and happiness of people. He is inspired to develop and provide these products through businesses that are committed to guiding their customers on their Personal Path to Awesome. Mark is driven by his wife, Rita, and his three children to support their passions and deliver answers where none yet exist resulting in health, happiness, and smiles for everyone.
Chief Executive Officer, ACOVA Integrated Health
Chad Martinson currently serves as CEO of ACOVA Integrated Health, a company dedicated to delivering better health outcomes for individuals living with chronic conditions. As CEO, Chad directs ACOVA’s long-term growth planning by building strong industry relationships and sourcing new business development opportunities that compliment and add value to the company. Chad currently also serves as Director of Q-State Biosciences, Pairnomix, Proximagen, MOBE and Plymouth Guarantee. Prior to joining ACOVA, Chad held a number of leadership roles in the fields of corporate finance, business unit finance, sales and marketing, and operations. Most recently, Chad served as CFO and Executive Vice President of Operations at Upsher-Smith Laboratories and Director of Pairnomix. He also previously served as VP of Finance and Business Development at Medtronic in the company’s neuro division, and spent eight years at KPMG in the audit practice. He holds a B.A. from Luther College in Decorah, Iowa, and an M.B.A. from Harvard Business School in Boston, Massachusetts.
Senior Vice President & Chief Legal Counsel, United National Corporation
Dave Knudson is Senior Vice President and Chief Legal Counsel at United National Corporation, where he provides legal and advisory services to the company. Prior to this role, he served as Sr. Vice President – Strategic Advisor for Sanford Health, the largest rural not-for-profit healthcare system in the country. He also practiced law for 35 years at Davenport, Evans, Hurwitz and Smith in Sioux Falls, focusing on healthcare, banking and corporate transactions. Throughout his career as a lawyer and advisor, Dave has worked closely with Mr. Denny Sanford, founder and chairman of United National Corporation and benefactor of Sanford Health, to organize more than $1.5 billion in charitable gifts to various non-profits. Dave has a long-time interest in public service. He was Chief of Staff to South Dakota Governor Bill Janklow in 1995 and 1999, served four terms in the South Dakota State Senate, and served as the Senate Majority Leader from 2007 to 2010. He ran unsuccessfully in the 2010 Republican primary for Governor of South Dakota. He also served on the board of several organizations, including the Sioux Falls Development Foundation and the Sioux Falls Area Chamber of Commerce. A native of Yankton, South Dakota, Dave is a graduate of Harvard College and the New York University School of Law. He received an M.B.A. from the University of South Dakota School of Business.
Dr. Steven Hyman
Director, Stanley Center for Psychiatric Research
Steven Hyman currently serves as the director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and is the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. In addition to these roles, Steven is President of the American College of Neuropsychopharmacology, a Distinguished Life Fellow of the American Psychiatric Association, a fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Medicine. Previously, Steven served as provost of Harvard University from 2001 to 2011 and as Director of the National Institute of Mental Health (NIMH) from 1996 to 2001. He holds a B.A. from Yale University, an M.A. from the University of Cambridge, and an M.D. from Harvard Medical School.
Andrew Ross is a lifelong entrepreneur and private investor with a focus on early-stage investments in biotechnology, collaborative consumption, cause-focused enterprise.
Dr. Jonathan Thomas
Governing Board Chair, California Institute for Regenerative Medicine
Jonathan Thomas (“JT”) is the Chair of the Governing Board of the California Institute for Regenerative Medicine (CIRM), a public agency dedicated to advancing stem cell research and developing cures for people in need. As head of the board, JT is responsible for all aspects of CIRM’s $3 billion funding program. Before joining CIRM he was a Co-Founding Partner at Saybrook Capital, an investment banking and private equity firm, where he led an early round of financing for Advanced Cell Technology (now Ocata Therapeutics). JT’s legal experience includes clerking for White House Counsel Lloyd Cutler in the last year of the Carter Administration and clerking for the Honorable George Mackinnon of the United States Circuit Court of Appeals for the District of Columbia Circuit. JT holds a Bachelor’s degree from Yale University where he graduated summa cum laude, a J.D. from Yale, and a Ph.D. from Oxford University, where he was a George C. Marshall Scholar.
Executive Chair, QurAlis
Jonathan Fleming currently serves as Chairman of the Board at QurAlis and at Enclear Therapies, two ALS-focused companies that were spun out of Q-State Biosciences. Jonathan also serves as a director of several other biotechnology companies, including SQZ Biotech and Continuus Pharmaceuticals. Previously, he was the President, CEO, and Chief Business Officer at Q-State. Jonathan has been a life science entrepreneur for more than 33 years, starting and financing growth companies in the United States, Europe, Israel and Asia. He served as the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, which raised over $1 billion in early stage capital resulting in 21 IPOs and over 40 M&A transactions. He also co-founded several companies including Synaptic Pharmaceuticals (acquired by Lundbeck), Memory Pharmaceuticals (acquired by Roche), and Hypnion Pharmaceuticals (acquired by Lilly). Jonathan has been a senior lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a course on business strategy for life science managers. He holds a Master’s degree in Public Administration from Princeton University and a Bachelor’s degree in Political Science from the University of California, Berkeley.
Dr. Adam E. Cohen
Q-State Co-Founder & Professor, Harvard University
Adam E. Cohen is a professor in the departments of Chemistry and Chemical Biology and Physics at Harvard, with secondary appointments in the Center for Brain Science and the Harvard Stem Cell Institute. He is also an investigator with the Howard Hughes Medical Institute. At Harvard, Adam and his lab have developed numerous tools to study biological molecules and cells, most notably Optopatch technology. This first-of-its-kind technology uses genetically encoded fluorescent reporters to examine electrical activity in neurons. The Optopatch technology is commercially licensed exclusively to Q-State, where it is used to characterize cellular models of nervous system disorders. Adam has received Young Investigator Awards from the Office of Naval Research, the Dreyfus Foundation, the Sloan Foundation, and many other organizations. Technology Review Magazine named Adam one of the top 35 US technological innovators under the age of 35, Popular Science named him one of their “Brilliant Ten” top young scientists, and President Obama awarded him a Presidential Early Career Award for Scientists and Engineers. Adam holds an A.B. in chemistry and physics from Harvard, a Ph.D. in experimental biophysics from Stanford, and a Ph.D. in theoretical physics from the University of Cambridge.
Dr. Kevin Eggan
Q-State Co-Founder & Professor, Harvard University
Kevin Eggan is a professor in the department of Stem Cell and Regenerative Biology at Harvard and Director of the Stem Cell program at the Broad Institute’s Stanley Center. He garnered international recognition for his seminal work in stem cell biology, receiving the MacArthur Foundation “Genius Grant” in 2006 and being selected as a Howard Hughes Medical Institute Early Career Scientist. His current research focuses on using stem cell technologies to better understand nervous system disorders such as amyotrophic lateral sclerosis (ALS) and schizophrenia, with the aim of developing new therapeutics. Kevin received a B.S. from the University of Illinois and a Ph.D. from the Massachusetts Institute of Technology.
Dr. Orrin Devinsky
Director, NYU Comprehensive Epilepsy Center
Dr. Orrin Devinsky is the Director of the NYU Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He is also a Professor of Neurology, Neurosurgery and Psychiatry at NYU Langone School of Medicine. At NYU, Orrin specializes in treating children and adults with epilepsy and also leads clinical studies to better understanding the neurophysiology of epilepsy and testing the safety and efficacy of new treatments. His research has been instrumental in developing many of the anti-epileptic drugs available on the market or in clinical trials today, and as a result he was selected by TIME Magazine as one of the 50 most influential people in healthcare (2018). He received a B.S. and M.S. from Yale University and an M.D. from Harvard Medical School.
General Manager, IBM Watson Health
Paul Roma is a recognized leader in the analytics and artificial intelligence industries, with over 20 years of experience in the healthcare technology and digital transformation sectors. He excels in creating new markets with sustainable value and now serves as the global General Manager for IBM Watson Health. Paul’s select prior achievements include serving as the Chief Executive Officer of Ciox Health as well as Global Chief Analytics Officer, Product and Innovation Lead, and National Technology Lead – Healthcare and Life Sciences at Deloitte, adjunct faculty at Singularity University, and contributor to the MIT Media Lab. Paul received his B.S.E in mechanical engineering from the University of Michigan.
Dr. Matthew Might
Director, Hugh Kaul Precision Medicine Institute, University of Alabama-Birmingham
Dr. Matthew Might is the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) School of Medicine. There, he leverages his expertise in genomics and informatics to drive the Institute’s strategic direction. Formerly, Matthew served as a member of the White House’s Precision Medicine Initiative and was an Associate Professor in the School of Computing at the University of Utah. He received a CAREER Award from the National Science Foundation, and in 2014 he was appointed one of six Presidential Scholars at the University of Utah. Matthew received a Ph.D. in Computer Science from Georgia Institute of Technology. His son, Bertrand, was the first patient ever discovered with a rare disorder known as N-Glycanase deficiency. Matt posted an essay online that catalyzed the creation of the NGLY1 patient community, the remarkable aftermath of which has been chronicled in publications such as The New Yorker and Der Spiegel.
Dr. Sudhir Agrawal
Visiting Professor, University of Massachusetts Medical School; Founder, Arnay Sciences
Sudhir Agrawal, D. Phil, FRSC is a Visiting Professor in the Department of Medicine at The University of Massachusetts Medical School, a member of the Business Advisory Board of The Harvard Medical School’s Initiative for RNA Medicine, and a member of advisory board of Lytix biopharma. He is founder and member of Arnay Sciences LLC. He is also a founder of Idera Pharmaceuticals and had held various leadership roles within the company, including Chairman, CEO, President of Research, and Chief Scientific Officer. Sudhir’s research interests focus on the discovery and development of nucleic acid therapeutics, including antisense oligonucleotides (ASOs). He has edited four books on oligonucleotides and antisense technology, published hundreds of research papers on these topics, and is listed as a co-inventor of more than 400 patents worldwide.
Dr. William Pullman
President, Proximagen Ltd
As President of Proximagen, an early clinical stage drug development company, Dr. William (Bill) Pullman oversees the company’s strategic direction and scientific affairs, including pipeline selection and development, and all clinical, medical, and regulatory operations. Before joining Proximagen, Bill served as Chief Scientific Officer of Upsher-Smith Laboratories. He also formerly held positions as Chief Research and Development Officer and Chief Development Officer at Dyax Corp., Chief Medical Officer at Cubist Pharmaceuticals, and Senior Vice President, Exploratory Development at TransForm Pharmaceuticals. Bill completed his primary medical training at the University of Western Australia and is a fellow of the Royal Australian College of Physicians. He also received a Ph.D. in Medicine and Clinical Science (Immunology) from the Australian National University.